Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01934335
Other study ID # 201301763
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date October 2013
Est. completion date December 21, 2018

Study information

Verified date October 2021
Source University of Iowa
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this project is to examine whether treatment with vandetanib has an effect on the tumor cells in breast cancer by examining tissue markers.


Description:

The purpose of this research study is to test whether vandetanib has an effect on tumor growth markers. Vandetanib is not approved by the FDA for use in treating breast cancer. This study will compare vandetanib to a placebo. The proposed study is designed to determine the change in Ki-67 expression on paired breast cancer samples obtained before and after treatment with vandetanib. Other tumor markers including RET, TUNEL and phosphorylation specific levels of ERK1/2, AKT and mTOR will also be assessed on the paired samples. Those who have a core biopsy of the breast which demonstrates invasive breast cancer and requires surgical excision of the lesion will be eligible for inclusion in the study. The tyrosine kinase inhibitor, vandetanib 300 mg, will be given once a day for 7-14 days prior to surgery. Following surgery, tissue markers would be analyzed on each of the paired samples, allowing for rapid assessment of in vivo response to TKI treatment.


Recruitment information / eligibility

Status Terminated
Enrollment 12
Est. completion date December 21, 2018
Est. primary completion date December 21, 2018
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria: - Patients with core breast biopsy that, on pathology review, demonstrates invasive breast cancer and are determined to need surgical excision of the lesion. All subtypes of invasive breast cancer will be enrolled. Core biopsy specimens of enrolled patients will be stained for RET by immunohistochemistry and scored, however, patients will not be excluded according to RET expression. - Female gender - Age >/= 18 years of age - ECOG performance status </= 2 - Life expectancy of greater than 6 months - Ability and willingness to provide informed consent to participate in study Exclusion Criteria: - Prolonged QT interval (QTc > 480 milliseconds) on screening EKG or congenital long QT syndrome - Any concomitant medications that are known to be associated with Torsades de Pointes or QT elongation (see appendix 2). - Hypertension not controlled by medical therapy (systolic BP greater than 160 millimeters of mercury [mmHg] or diastolic blood pressure great than 100 mmHg). - Patients taking metformin or digoxin. - History of arrhythmia (multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia), which is symptomatic or requires treatment (CTCAE Grade 3), symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia. Patients with atrial fibrillation controlled by medication are permitted. - Significant cardiac event (e.g., myocardial infarction), superior vena cava syndrome, New York Heart Association (NYHA) classification of heart disease =2 within 12 weeks, or presence of cardiac disease that in the opinion of the Investigator increases the risk of ventricular arrhythmia. - Serum calcium or magnesium outside the institutional range of normal. - Serum Potassium < 4.0 mmol/L or above 5.0 mmol/L - Creatinine clearance < 50 ml/min - PT > 12 seconds or PTT > 31 seconds - Platelet count of < 100,000 - Serum bilirubin greater than 1.5 mg/dl - Alanine aminotransferase (ALT) > 50 U/L, aspartate aminotransferase (AST) > 65 U/L, or alkaline phosphatase (ALP) > 250 U/L - Any cytotoxic treatments, such as neoadjuvant chemotherapy, planned before subsequent surgical procedure. - Previous exposure to Vandetanib - Previous enrollment or randomization in this study - Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and staff at UIHC). - Previous or current malignancies of other histologies within the last 5 years, with the exception of in situ carcinoma of the cervix, and adequately treated basal cell or squamous cell carcinoma of the skin. - Patients who have received prior surgical site radiation. - Patients on CYP3A4 inhibitors or inducers (see appendix 1). - Inability to test core biopsy for study markers - Pregnancy or lactation at the time of study entry. (Note: Pregnancy testing must be performed within 2 weeks prior to randomization according to institutional standards for women of childbearing potential.)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Vandetanib

Other:
Placebo


Locations

Country Name City State
United States University of Iowa Hospitals and Clinics Iowa City Iowa

Sponsors (2)

Lead Sponsor Collaborator
Ronald Weigel AstraZeneca

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Percent Change From Baseline in RET Expression Observed 2 Weeks Post-treatment Results will be stratified by RET gene expression, a negative prognostic indicator in breast cancer, to demonstrate that RET is a marker of response. 2 weeks
Primary Percent Change From Baseline in Ki-67 Cells Observed 2 Weeks Post-treatment Pre- and post-treatment samples will be assessed by immunohistochemistry for positivity for Ki-67. 2 weeks
Secondary Percent Change From Baseline in TUNEL Observed 2 Weeks Post-treatment Pre- and post-treatment samples will be assessed by immunohistochemistry for positivity for TUNEL. 2 weeks
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03595592 - Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer Phase 3
Recruiting NCT05383196 - Onvansertib + Paclitaxel In TNBC Phase 1/Phase 2
Recruiting NCT06158217 - Effect of Ultrasound Combined With Microbubbles on Blood Perfusion in Invasive Breast Cancer
Active, not recruiting NCT04448886 - Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC Phase 2
Completed NCT02773784 - Comparison of CNB and Surgical Specimens for ER, PgR, HER2 Status and Ki67 Index in Invasive Breast Cancer.
Recruiting NCT01509781 - Suction Drain Versus the Use of Adaptive Skin Sutures After Mastectomy ± Axillary Lymphadenectomy; a Prospective Randomised Study Phase 3
Completed NCT04478669 - Digital Breast Tomosynthesis (DBT) to Improve Assessment of Resection Margins in Invasive Breast Cancer
Recruiting NCT04553770 - Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer Phase 2
Recruiting NCT04677816 - Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients Phase 2
Completed NCT00507611 - Axillary Lymph Node Status After Completion of Preoperative Neoadjuvant Systemic Chemotherapy in Patients N/A
Completed NCT00581750 - Molecular Genetic Basis of Invasive Breast Cancer Risk Associated With Lobular Carcinoma in Situ
Completed NCT03304171 - Overall Diet Quality and Breast Cancer Risk N/A
Completed NCT03709186 - Radiomic Markers for Breast Cancer Metastasis and Treatment Response Using MRI
Terminated NCT03361800 - Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC Early Phase 1
Recruiting NCT04648904 - Study of a Shortened Radiation Therapy Schedule in People With Breast Cancer Early Phase 1
Recruiting NCT06328465 - fREEDOM: REsonance for Early Detection Of Breast Cancer Metastases N/A
Active, not recruiting NCT03109522 - Axillary Reverse Mapping (ARM) Technique N/A
Recruiting NCT03987555 - Paclitaxel Therapeutic Drug Monitoring in Cancer Patients
Recruiting NCT03497702 - Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer Phase 2
Recruiting NCT05795101 - TRUDI: TDXD+Durva in HER2+/Low IBC Phase 2